Hologic (NSDQ:HOLX) announced that it agreed to acquire molecular diagnostic test maker Biotheranostics for approximately $230 million. Privately held, commercial-stage Biotheranostics provides molecular diagnostics for breast and metastatic cancers. Both of its tests are PCR-based gene expression tests which have been validated in large studies in areas of oncology with unmet needs and high growth potential, […]
Queensbury, N.Y.-based Delcath (NSDQ:DCTH) announced last week that it plans to pare its workforce by about 20%, the latest in a series of layoff announcements from the oncology devices maker. This is the 3rd time this year that Delcath has announced imminent layoffs, having announced smaller cuts in April and larger layoffs in January.